Coronary artery bypass grafting is a more invasive procedure where surgeons use blood vessels from another part of the body ...

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed ...

The Stanislaus Medical Society is recognizing the career of a leading cardiologist in Modesto. Dr. Satnam Ludder is receiving ...

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having excessive bleeding in ...

Tamim Iqbal has undergone angioplasty after suffering a massive heart attack during Mohammedan Sporting Club’s match against the Shinepukur Cricket Club in the ongoing Dhaka Premier Division Cricket ...

Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) ...

IVL is a newer treatment for calcified coronary arteries that treats blockages by fracturing the calcium within the artery wall, potentially allowing for vessel expansion and better stent placement.

The global bioabsorbable stents market size was US$ 221.5 million in 2021. The global bioabsorbable stents market is forecast to grow to US$ 351.5 million by 2030 by growing at a compound annual ...

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...

IVL is a newer treatment for calcified coronary arteries that treats blockages by fracturing the calcium within the artery wall, potentially allowing for vessel expansion and better stent placement.